Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

Conclusion Saracatinib is a novel oral Src kinase inhibitor that was well tolerated but failed to meet its primary endpoint of improvement in 4 month progression-free survival as a single agent in previously treated metastatic colorectal cancer patients.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research